Methyl 2-[(8-oxo-13-oxa-10,12,14,16-tetrazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),3,5,9,11,14-heptaen-6-yl)oxy]acetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl 2-[(8-oxo-13-oxa-10,12,14,16-tetrazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2(7),3,5,9,11,14-heptaen-6-yl)oxy]acetate
• 化学式: C₁₄H₈N₄O₅
• 分子量: 312.24
• InChiKey: UZOADTYWADQVMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  117
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• [EN] DIAZAFLUORENONE IL-8 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS D'IL-8 A BASE DE DIAZAFLUORENONE
  申请人：WARNER LAMBERT CO

  公开号：WO2001079209A2

  公开（公告）日：2001-10-25

  The present invention relates to diazafluorenone derivatives of Formula I which are IL-8 receptor antagonists useful as pharmaceutical agents, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to methods of treating a chemokine-mediated disease state in a mammal, including a human. The diazafluorenones of the present invention are useful in the treatment of chemokine-mediated diseases such as, psoriasis, cancer, asthma, Alzheimer's disease, inflammatory bowel disease, graft versus host reaction, or allograft rejections in a mammal, including a human.